Non-Small Cell Lung Cancer | Second Opinion: Investigators Discuss How They Apply Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer with an EGFR Mutation
Featuring
perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel
W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu,
moderated by Dr Yu, including the following topics:
Introduction (0:00)
Contemporary Care for Patients with
Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR
Mutation — Dr Langer (2:08)
Evolving First-Line Treatment for Metastatic
NSCLC with an EGFR Mutation — Dr Goldman (22:37)
Biological Rationale for and Emerging Role of
Antibody-Drug Conjugates in the Management of NSCLC with an EGFR
Mutation — Dr Yu (43:23)
Other Emerging Strategies for Relapsed
Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33)
Current and Future Management of NSCLC with
an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15)
Management of Toxicities Associated with
Available and Emerging Therapies for NSCLC with an EGFR Mutation —
Dr Neal (1:38:44)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.